Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 11, 2023
m6A-Modified circTET2 Interacting with HNRNPC Regulates Fatty Acid Oxidation to Promote the Proliferation of Chronic Lymphocytic LeukemiaZijuan Wu, Xiaoling Zuo, Wei Zhang, et al.
Frontiers in Oncology|April 30, 2021
Conventional Treatments Cannot Improve Outcomes of Early-Stage Primary Breast Marginal Zone LymphomaHailing Liu, Jing Zhang, Lin Quan, et al.
Discover Oncology|May 3, 2026
A lipid nanoparticle-based peptide-proteolysis-targeting chimera degrades BCL6 for diffuse large B-cell lymphoma treatmentShiwei Liu, Xueying Gao, Xuan Ye, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 17, 2023
Low T3 syndrome as a predictor of poor prognosis in peripheral T-cell lymphomasWenyi Li, Rui Gao, Weiting Wang, et al.
Annals of Hematology|December 27, 2023
Investigation of fatty acid metabolism in chronic lymphocytic leukemia to guide clinical outcome and therapyBihui Pan, Zhangdi Xu, Kaixin Du, et al.
Oncotarget|September 24, 2017
Correction: Endothelial microparticles delivering microRNA-155 into T lymphocytes are involved in the initiation of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantationRan Zhang, Xiaoxiao Wang, Mei Hong, et al.
Oncotarget|April 21, 2017
Endothelial microparticles delivering microRNA-155 into T lymphocytes are involved in the initiation of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantationRan Zhang, Xiaoxiao Wang, Mei Hong, et al.
British Journal of Haematology|June 2, 2026
Concurrent antiviral-immunochemotherapy strategy safely overcomes high hepatitis B viral load barrier in diffuse large B-cell lymphoma: A multicentre cohort studyYuxiao Zhao, Jingjing Guo, Xiran Wang, et al.
Chinese Medical Journal|October 15, 2023
Chidamide plus prednisone, cyclophosphamide, and thalidomide for relapsed or refractory peripheral T-cell lymphoma: A multicenter phase II trialJinhua Liang, Li Wang, Xiaodong Wang, et al.
American Journal of Hematology|April 26, 2026
Outcomes With First-Line PD1 Inhibitors in Extranodal NK/T-Cell Lymphoma: A Comparative Analysis From a 755-Patient Multicenter CohortHailing Liu, Mei Sun, Chunling Wang, et al.
Pageof 3